The development of mesenchymal stem cells (MSCs) as cell-based drug delivery vectors for
numerous clinical indications, including cancer, has significant promise. However, a …

Oncolytic viruses (OVs) infect, multiply, and finally remove tumor cells selectively, causing no
damage to normal cells in the process. Because of their specific features, such as, the ability …

Mesenchymal stem cells (MSCs) are non-hematopoietic progenitor cells, which can be
isolated from different types of tissues including bone marrow, adipose tissue, tooth pulp …

Mesenchymal stem cells (MSCs) can exhibit a marked tropism towards site of tumors. Many
studies have reported that tumor progression and metastasis increase by MSCs. In contrast …

Human mesenchymal stem cells (MSCs) communicate with other cells in the human body
and appear to “home” to areas of injury in response to signals of cellular damage, known as …

Despite recent advances in both surgery and chemoradiotherapy, mortality rates for
advanced cancer remain high. There is a pressing need for novel therapeutic strategies; one …

EXECUTIVE SUMMARY The University of Vermont College of Medicine and the Vermont
Lung Center, with support of the National Heart, Lung, and Blood Institute (NHLBI), the …

Δ24-RGD is an infectivity-augmented, conditionally replicative oncolytic adenovirus with
significant antiglioma effects. Although intratumoral delivery of Δ24-RGD may be effective …

In recent years, in light of the promising potentials of mesenchymal stromal/stem cells
(MSCs) for carrying therapeutic anticancer genes, a complete revisitation on old …

Oncolytic virotherapy is a therapeutic approach that uses replication-competent viruses to
kill cancers. The ability of oncolytic viruses to selectively replicate in cancer cells leads to …